Development of a dynamic multiple reaction monitoring LC-APCI-MS/MS method for quantification of ten nitrosamines in ranitidine API with simple extraction approach

Year 2024, Volume: 7 Issue: 2, 66 - 75, 31.12.2024

Murat Emrah Maviş , Neşe Ular Çağatay , Gökçe Göksu Gürsu

https://doi.org/10.46239/ejbcs.1366734

Abstract

Nitrosamines (NAs) are classified as probable or possible human carcinogens by the International Agency for Research on Cancer (IARC) and the presence of these impurities has resulted in numerous drug recalls from the market. In April 2020, ranitidine which is prescribed to reduce the amount of acid secreted by the stomach has been recalled owing to contamination with NAs. In this work, a simple and sensitive method for simultaneous determination of 10 NAs were developed, utilizing atmospheric pressure chemical ionisation source coupled liquid chromatography tandem mass spectrometer (LC-APCI-MS/MS). By performing dynamic multiple reaction monitoring (dMRM) mode, 10 NAs were separated on a Poroshell HPH C18 (4.6 x 150 mm, 2.7 µm) column with gradient elution implementing mobile phase A consisting of 0.2 % formic acid in water and mobile phase B consisting of methanol in 17 min. The proposed analytical method was successfully implemented in active pharmaceutic ingredient (API) of ranitidine with a water-based extraction procedure. Good linearity with a correlation coefficient (R2) ≥ 0.994 was accomplished over the concentration in range of 0.5–50 ng/mL. The limits of detection (LODs) ranged in 0.06–0.17 ng/mL and limits of quantitation (LOQs) ranged in 0.21-0.58 ng/mL of the method met thresholds of US Food and Drug Administration (US-FDA) and European Medicines Agency (EMA) for testing of NAs. The accuracy of the developed method ranged from 83.1% to 111.9 % and the percent relative standard deviation (%RSD) was ≤ 8.9.

Keywords

Ranitidine, Liquid chromatography, Mass spectrometry, Simultaneous determination, N-nitrosamines

References

• Aldawsari FS, Alshehry YM, Alghamdi TS. 2021. N-nitrosodimethylamine (NDMA) Contamination of Ranitidine Products: A Review of Recent Findings. J Food Drug Anal. 29(1): 39–45.
• AlShehri YM, Alghamdi TS, Aldawsari FS. 2020. HS-SPME-GC-MS as an Alternative Method for NDMA Analysis in Ranitidine Products. J Pharma Biomed Anal. 191:N113582.
• Bharate SS. 2021. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. J Med Chem. 64, 2923-2936.
• Campillo CG, Belda MP, Campillo N, Hernandez-Cordoba M. 2021. Development of a new methodology for the determination of N-nitrosamines impurities in ranitidine pharmaceuticals using microextraction and gas chromatography-mass spectrometry. Talanta, 223: 121659.
• Giménez-Campillo C, Pastor-Belda M, Campillo N, Hernández-Córdoba M, Viñas, P. 2020. Monitoring N-Nitrosamines impurities in ranitidine pharmaceuticals using microextraction and gas chromatography-mass spectrometry. Talanta. 121659.
• Health Canada. 2019. Impurities found in certain angiotensin II receptor blocker (ARB) products, also known as Sartans. Information update. Available at: https:// www.canada.ca/en/health-canada/services/drugs-health-products/complianceenforcement/ information-health-product/drugs/angiotensin-receptor-blocker. html. Accessed January 7, 2021.
• King FJ, Searle AD, Urquhart MW. 2020. Ranitidine-Investigations into the Root Cause for the Presence of N‑Nitroso‑N,N‑dimethylamine in Ranitidine Hydrochloride Drug Substances and Associated Drug Products. Org. Process Res. Dev. 24:2915–2926.
• Lim HH, Oh YS, Shin HS. 2020. Determination of N-nitrosodimethylamine and N-nitrosomethylethylamine in drug substances and products of sartans, metformin and ranitidine by precipitation and solid phase extraction and gas chromatography–tandem mass spectrometry. J Pharma Biomed Anal. 189:113460.
• Liu J, Zhao Z, Yang X., Jin Y, Liu X, Wang C, Zhang Z. 2021. Determination of N-nitrosodimethylamine in Ranitidine Dosag Forms by ESI-LC-MS/MS; Applications for Routine Laboratory Testing. Iran J Pharm Res. 20 (4): 255-264.
• Masada S, Tsuji G, Arai R, Uchiyama N, Demizu Y, Tsutsumi T, Abe Y, Akiyama H, Hakamatsuka T, Izutsu K, Goda Y, Okuda H. 2019. Rapid and efficient high performance Liquid chromatography analysis of N-nitrosodimethylamine impurity in valsartan drug substance and its products. Sci Rep. 9:11852.
• Ngongang AD, Duy SV, Sauve S. 2015. Analysis of nine N-nitrosamines using liquid chromatography-accurate mass high resolution mass spectrometry on a Q-Exactive instrument. Anal Methods. 7(14):5748–5759.
• Parra MK, Josepha JF. 2019. NDMA impurity in valsartan and other pharmaceutical products:Analytical methods for the determination of N-nitrosamines J Pharma Biomed Anal. 164:536–549.
• Ripollés C, Pitarch E, Sancho JV, López FJ, Hernández F. 2011. Determination of eight nitrosamines in water at the ng L1 levels by liquid chromatography coupled to atmospheric pressure chemical ionization tandem mass spectrometry. Anal Chim Acta. 702:62e71.
• Schmidtsdorff S, Schmidt AH. 2019. Simultaneous detection of nitrosamines and other sartan-related impurities in active pharmaceutical ingredients by supercritical fluid chromatography. J Pharma Biomed Anal. 174:151–160.
• Shaik KM, Sarmah B, Wadekar GS, Kumar P. 2020. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques. Crit Rev Anal Chem. 52(1): 53-71.
• The European Directorate for the Quality of Medicines & HealthCare (EDQM). 2019. LC-MS/MS method for LOSARTAN potassium. Test method. Available at: https://www.edqm.eu/sites/default/files/de_lgl_losartan_method_parameters_nm ba_lcms.pdf. Accessed Accessed January 7, 2021.
• Tuesuwan B, Vongsutilers V. 2021. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control. J Pharm Sci. 110:3118−3128.
• U.S. Food & Drug Administration. 2018. Combined direct injection N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurity assay by GC/MS. Test method. Available at: https://www.fda.gov/media/117807/download. Accessed January 7, 2021.
• U.S. Food & Drug Administration. 2019. Combined N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) impurity assay by GC/MS-headspace. Test method. Available at: https://www.fda.gov/media/117843/download. Accessed January 7, 2021.
• U.S. Food & Drug Administration. 2019. GC/MS headspace method for detection of NDMA in valsartan drug substance and drug products. Test method. Available at: https://www.fda.gov/media/115965/download. Accessed January 7, 2021.
• U.S. Food & Drug Administration. 2019. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of NDMA in ranitidine drug substance and drug product. Test method. Available at: https://www.fda.gov/media/130801/download. Accessed December 1, 2020.
• U.S. Food & Drug Administration. 2019. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of NDMA in ranitidine drug substance and solid dosage drug product. Test method. Available at: https://www.fda.gov/media/131868/download. Accessed December 1, 2020.
• Wichitnithad W, Sudtanon O, Srisunak P, Cheewatanakornkool K, Nantaphol S, Rojsitthisak P. 2021. Development of a Sensitive Headspace Gas Chromatography−Mass Spectrometry Method for the Simultaneous Determination of Nitrosamines in Losartan Active Pharmaceutical Ingredients. ACS Omega. 6:11048−11058.
• Yokoo H, Yamamoto E, Masada S, Uchiyama N, Tsuji G, Hakamatsuka T, Demizu Y, Izutsu K, Goda Y. 2021. N-Nitrosodimethylamine (NDMA) Formation from Ranitidine Impurities: Possible Root Causes of the Presence of NDMA in Ranitidine Hydrochloride. Chem Pharm Bulletin. 69: 872–876.